Assignee: The Board of Regents of the University of Oklahoma

Location: Not specified.
No. of patents: 34

Number	Title	Issue Date
6994907	Carbon nanotube product comprising single-walled carbon nanotubes A carbon nanotube product formed from a metallic catalytic particle and single-walled carbon nanotubes deposited thereon. The catalytic particles preferably contain at least one metal from Group VIII, including for example Co, Ni, Ru, Rh, Pd, Ir, and Pt, and at leas...	02/07/2006
6962892	Metallic catalytic particle for producing single-walled carbon nanotubes A metallic catalytic particle for producing single-walled carbon nanotubes. The catalytic particles contain at least one metal from Group VIII, including for example Co, Ni, Ru, Rh, Pd, Ir, and Pt, and at least one metal from Group VIb including for example Mo, W an...	11/08/2005
6955800	Method and apparatus for producing carbon nanotubes A method and apparatus for catalytic production of carbon nanotubes. Catalytic particles are exposed to different process conditions at successive stages wherein the catalytic particles do not come in contact with reactive (catalytic) gases until preferred process c...	10/18/2005
6919064	Process and apparatus for producing single-walled carbon nanotubes A process and apparatus for catalytic production of single walled carbon nanotubes. Catalytic particles are exposed to different process conditions at successive stages wherein the catalytic particles do not come in contact with reactive (catalytic) gases until pref...	07/19/2005
6730659	Antimicrobial peptides and methods of use thereof Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of...	05/04/2004
6713283	Tyrosylprotein sulfotransferases Tyrosylprotein sulfotransferases and nucleic acids encoding the tyrosylprotein sulfotransferases are described. Dual isotopes of the enzyme and of the nucleic acids encoding the enzymes have been identified in human, mouse and C. elegans. The polypeptides and...	03/30/2004
6667036	Methods of treatment using antibodies to P-selectin glycoprotein ligand P-selectin has been demonstrated to bind primarily to a single major glycoprotein ligand on neutrophils and HL-60 cells, when assessed by blotting assays and by affinity chromatography of [3 H]glucosamine-labeled HL-60 cell extracts on immobili...	12/23/2003
6605455	Tyrosylprotein sulfotransferases and methods of use thereof Tyrosylprotein sulfotransferases and nucleic acids encoding the tyrosyiprotein sulfotransferases are described. Dual isotopes of the enzyme and of the nucleic acids encoding said enzymes have been identified in human, mouse and C. elegans. The polypeptide...	08/12/2003
6593459	Synthetic glycosulfopeptides and methods of synthesis thereof A new class of synthetic glycosulfopeptides (GSPs) which have one or more sulfated tyrosine residues and a glycan linked to the peptide, the glycan preferably including a sialyl Lewisx group or a sialyl Lewisa group. In a preferred v...	07/15/2003
6567693	Iontophoretic transdermal delivery device A conducting silicone matrix incorporating a suspension of a drug in ionized and non-ionized phases in an emulsion of a hydrophobic polymer. In one version, the drug is prepared as a concentrated aqueous suspension incorporated in a silicone matrix with a...	05/20/2003
6514701	Antimicrobial peptides and methods of use thereof Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitutio...	02/04/2003
6506382	Method for inhibiting reperfusion injury using antibodies to P-selectin glycoprotein ligand P-selectin has been demonstrated to bind primarily to a single major glycoprotein ligand on neutrophils and HL-60 cells, when assessed by blotting assays and by affinity chromatography of [3 H]glucosamine-labeled HL-60 cell extracts on immobili...	01/14/2003
6492152	Core 1 댣-galactosyl transferases and methods of use thereof Core 1 댣-galactosyl transferases and nucleic acids encoding the core 1 댣-galactosyl transferases are described. The enzymes and the nucleic acids encoding said enzymes have been identified in human, rat, mouse D. melanogaster and C. elegans....	12/10/2002
6470320	Digital disease management system The present invention relates to a method for improving the delivery of health care for patients. A first data signal being multimedia data which is indicative of a patient condition of a selected patient is input into a local computer. Clinical data, cos...	10/22/2002
6413487	Method and apparatus for producing carbon nanotubes A method and apparatus for catalytic production of carbon nanotubes. Catalytic particles are exposed to different process conditions at successive stages wherein the catalytic particles do not come in contact with reactive (catalytic) gases until preferre...	07/02/2002
6309639	Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand P-selectin has been demonstrated to bind primarily to a single major glycoprotein ligand on neutrophils and HL-60 cells, when assessed by blotting assays and by affinity chromatography of [3 H]glucosamine-labeled HL-60 cell extracts on immobili...	10/30/2001
6299812	Method for forming a fibers/composite material having an anisotropic structure A method for forming fibers/composite material having an anisotropic structure, comprising the steps of mixing an effective amount of fibers with a matrix material to form a deformable mixture containing less than about 96 weight percent of the fibers to ...	10/09/2001
6225071	Methods of screening for compounds which mimic galectin-1 Methods for treating and modulating an inflammatory response using compositions containing a primarily monomeric or primarily dimeric form of galectin-1. The dimeric form stimulates apoptosis of activated neutrophils while the monomeric form inhibits apop...	05/01/2001
6207420	Fusion protein systems designed to increase soluble cytoplasmic expression of heterologous proteins in Escherichia coli A fusion sequence having a carrier protein which is preferably an E. coli protein having a predicted solubility probability of at least 90% fused to a target heterologous peptide or protein, and a host cell (especially E. coli) transformed with, or having...	03/27/2001
6187337	Rapidly dissolving dosage form A particulate support matrix, and a dosage form made therefrom, and processes for making such support matrices and dosage forms, which disintegrate or dissolve in a matter of just a few seconds once placed into an aqueous environment. First, a porous part...	02/13/2001
6187296	Lysine decarboxylase inhibitors for the prevention and treatment of periodontal disease An agent, ଱-difluoromethyl lysine (DEML) or ଱-monofluoromethyl lysine (MFML), which inhibits activity of lysine decarboxylases produced by bacteria associated with periodontal tissues. Inhibition of the activity of such lysine decarboxylases c...	02/13/2001
6119036	Iontophoretic transdermal delivery device A conducting silicone matrix incorporating a suspension of a drug in ionized and non-ionized phases in an emulsion of a hydrophobic polymer. In one version, the drug is prepared as a concentrated aqueous suspension incorporated in a silicone matrix with a...	09/12/2000
6107039	Assays using base protected table 1 The present invention is directed to protected thiol analogs of pyrimidine bases for syntheses of DNA and RNA by chemical or enzymatic methods. The subject analogs include reagents suitable for DNA or RNA synthesis via phosphoramidite, H-phosphonate or ph...	08/22/2000
6071879	Method for the treatment of bacterial infection The present invention contemplates a composition and method for treating a bacterial infection in a mammal. Comprising/administering a therapeutically effective amount of a peptide derived from CAP37 protein. In a preferred version, the composition and me...	06/06/2000
6071732	Tyrosylprotein sulfotransferases, nucleic acids encoding tyrosylprotein sulfotransferases, and methods of use thereof Tyrosylprotein sulfotransferases and nucleic acids encoding the tyrosylprotein sulfotransferases are described. Dual isotopes of the enzyme and of the nucleic acids encoding said enzymes have been identified in human, mouse and C. elegans. The polypeptide...	06/06/2000
6066337	Method for producing a rapidly dissolving dosage form A particulate support matrix, and a dosage form made therefrom, and processes for making such support matrices and dosage forms, which disintegrate or dissolve in a matter of just a few seconds once placed into an aqueous environment. First, a porous part...	05/23/2000
6054315	Method for making activated neutrophils recognizable to macrophages Methods for treating and modulating an inflammatory response using compositions containing a primarily monomeric or primarily dimeric form of galectin-1. The dimeric form stimulates apoptosis of activated neutrophils while the monomeric form inhibits apop...	04/25/2000
6053269	Vehicle/bridge vibration mitigation assembly A vibration mitigation assembly for mitigating vibration of a bridge as a vehicle travels across the bridge is provided. The vibration mitigation assembly includes a plurality of adjustable actuator assemblies having a first fluid chamber and a second flu...	04/25/2000
5989868	Fusion protein systems designed to increase soluble cytoplasmic expression of heterologous proteins in esherichia coli A fusion sequence having a carrier protein which is preferably an E. coli protein having a predicted solubility probability of at least 90% fused to a target heterologous peptide or protein, and a host cell (especially E. coli) transformed with, or having...	11/23/1999
5919637	Method for identifying reduced binding between GMP-140 and GMP-140 ligand A method using compounds inhibiting binding reactions involving GMP-140 to modulate an inflammatory response. The method is based on the discovery that GMP-140, released from the storage granules of platelets, endothelial cells, and megakaryocytes, and re...	07/06/1999
5877151	Method for inhibiting production of tumor necrosis factor The present invention contemplates a composition and method for treating septic shock in a mammal or as a prophylactic treatment prior to a surgical procedure, comprising administering a therapeutically effective amount of a bacterial lipopolysaccharide b...	03/02/1999
5693472	Detection of cryptosporidium parvum A method and kit for the detection of Cryptosporidium parvum in aquatic and biological samples such as surface water or feces. The method relies on the use of primers to detect all or a portion of at least one DNA sequence characteristic of C. parvum, the...	12/02/1997
5580771	DNA encoding mammalian phosphodiesterases The present invention relates to novel purified and isolated nucleotide sequences encoding mammalian Ca2+ /calmodulin stimulated phosphodiesterases (CaM-PDEs) and cyclic-GMP-stimulated phosphodiesterases (cGS-PDEs). Also provided are the corres...	12/03/1996
5115673	Non-destructive method for determining elastic moduli of material A non-destructive method for determining elastic moduli of isotropic or anisotropic or homogeneous or nonhomogeneous material. The material is subjected to x-radiation for determining the density of the material at a sufficient number of discrete measurem...	05/26/1992

PatentStorm

Bizarre Patents

PatentStorm News

Assignee: The Board of Regents of the University of Oklahoma